Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alon Ben-Noon
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 1.72
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -123.42
Financials
Net Income
$-3.21MEBITDA
$-3.19MFree Cash Flow
$-1.84MEPS (diluted)
$-2.60Shares Outstanding (diluted)
1.28M+368.6%Operating Expenses
$3.20MCash & Debt
$166.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-11.13M | $-8.80 |
| 2024 | $0.00 | $-10.21M | $-11.00 |
| 2023 | $0.00 | $-10.11M | $-16.60 |
| 2022 | $0.00 | $-12.34M | $-21.40 |
| 2021 | $0.00 | $-4.04M | $-4.60 |
| 2020 | $0.00 | $-2.83M | $-10.20 |
| 2019 | $0.00 | $-1.23M | $-4.40 |
Valuation
NRSNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-23.81%Social Signal Score
Mentions (8)
- Newsprnewswire.com·20d ago·Negative
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data Expanded package to include new neurofilament light chain (NfL) analysis; Health Canada confirms March 2027 filing timeline Submission would be PrimeC's first marketing application in any jurisdiction, potentially addressing approximately 4,000 Canadians living with ALS CAMBRIDGE, Mass., Nov. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
View source ↗ - Newsprnewswire.com·24d ago·Neutral
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 Presentation will highlight how findings from the PARADIGM program are informing the clinical development strategy for PARAGON CAMBRIDGE, Mass., Oct. 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
View source ↗ - Newsprnewswire.com·34d ago·Positive
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury Patent application seeks protection for PrimeC use in concussion, blast-related brain injury and chronic traumatic encephalopathy (CTE) Positions PrimeC for potential expansion beyond ALS into an indication affecting millions worldwide, with no approved disease-modifying therapy Filing supports opportunities for research partnerships CAMBRIDGE, Mass., Oct. 19, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
View source ↗ - Newsprnewswire.com·40d ago·Negative
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027 CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
View source ↗ - Newsprnewswire.com·55d ago·Neutral
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mass., Sept. 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
View source ↗ - Newsprnewswire.com·58d ago·Neutral
NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd.
View source ↗ - Newsprnewswire.com·83d ago·Neutral
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly reduce overall development costs, complemented by a parallel regulatory pathway in Canada. CAMBRIDGE, Mas
View source ↗ - Newsprnewswire.com·101d ago·Neutral
NeuroSense Issues CEO Letter to Shareholders CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
View source ↗
Earnings
Typical surprise +38.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Sep 25$-2.06 vs $-3.90beat
- Tue, Jun 30$-3.90 vs $-3.90beat
- Tue, Mar 31$-0.23 vs $-0.07miss
- Wed, Dec 17$-2.60 vs $-0.87miss
- Fri, Aug 1$-0.14 vs $-0.22beat
- Mon, Apr 7$-0.06 vs $-0.10beat
Estimates and results for NRSN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NRSN officers and directors.
- Bought
- $400k
- Sold
- —
2 trades
0 trades
- Ben-noon Alonbought
- Eisenberg Orbought
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NRSN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
